ストックスクリーナーアプリを入手
58.64
1.54%
-0.92
アフターアワーズ：
58.64
前日終値:
$59.56
開ける：
$59.49
24時間の取引高:
115.66K
Relative Volume:
0.50
時価総額：
$1.23B
収益：
$486.82M
当期純損益:
$18.78M
株価収益率:
71.51
EPS:
0.82
ネットキャッシュフロー:
$100.45M
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
+6.08%
6か月 パフォーマンス:
-10.77%
1年 パフォーマンス:
+5.05%
1日の値動き範囲:
$58.02
$59.49
1週間の範囲:
$58.02
$60.99
52週間の値動き範囲:
$52.50
$70.81
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
名前
Ani Pharmaceuticals Inc
セクター
電話
(218) 634-3500
住所
210 MAIN STREET WEST, BAUDETTE, MN
ANIP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
58.64 | 1.23B | 486.82M | 18.78M | 100.45M | 0.82 |
|
ZTS
Zoetis Inc
|
170.90 | 77.10B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.47 | 42.82B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.39 | 42.45B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.73 | 20.09B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
151.82 | 15.37B | 2.24B | 385.90M | 440.10M | 3.73 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-11 | 開始されました | Leerink Partners | Outperform |
| 2024-10-11 | 開始されました | Piper Sandler | Overweight |
| 2024-03-15 | 開始されました | CapitalOne | Overweight |
| 2023-08-22 | 繰り返されました | H.C. Wainwright | Buy |
| 2023-03-01 | 開始されました | Guggenheim | Buy |
| 2022-09-07 | 開始されました | H.C. Wainwright | Buy |
| 2021-11-02 | 開始されました | Truist | Buy |
| 2020-05-07 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | 開始されました | Guggenheim | Buy |
| 2019-05-10 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | 繰り返されました | Canaccord Genuity | Buy |
| 2017-07-31 | 開始されました | Canaccord Genuity | Buy |
| 2017-02-22 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2016-06-23 | 開始されました | Raymond James | Strong Buy |
| 2016-05-24 | ダウングレード | Standpoint Research | Buy → Hold |
| 2015-11-13 | 開始されました | Standpoint Research | Buy |
| 2015-09-28 | アップグレード | ROTH Capital | Neutral → Buy |
| 2015-08-05 | 繰り返されました | Oppenheimer | Outperform |
| 2015-08-04 | 繰り返されました | ROTH Capital | Neutral |
| 2015-07-31 | 繰り返されました | Oppenheimer | Outperform |
| 2015-07-15 | 繰り返されました | ROTH Capital | Neutral |
| 2015-06-23 | 繰り返されました | Oppenheimer | Outperform |
| 2015-05-18 | 繰り返されました | ROTH Capital | Neutral |
| 2015-05-06 | 繰り返されました | Oppenheimer | Outperform |
| 2015-04-10 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2015-02-26 | 繰り返されました | ROTH Capital | Buy |
| 2015-02-18 | 繰り返されました | Oppenheimer | Outperform |
すべてを表示
Ani Pharmaceuticals Inc (ANIP) 最新ニュース
ANI Pharmaceuticals (NASDAQ:ANIP) Cut to Sell at StockNews.com - MarketBeat
9,843 Shares in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Bought by SG Americas Securities LLC - Defense World
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Investing in ANI Pharmaceuticals (NASDAQ:ANIP) three years ago would have delivered you a 53% gain - Yahoo Finance
StockNews.com Downgrades ANI Pharmaceuticals (NASDAQ:ANIP) to Sell - Defense World
ANI Pharmaceuticals to Present at the Guggenheim Biotech Conference - GlobeNewswire
ANI Pharma CEO Reveals Future Strategy: Key Insights Coming at Major Biotech Event - StockTitan
ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis - MarketBeat
Millennium Management LLC's Strategic Acquisition in ANI Pharmac - GuruFocus.com
ANI Maintains Course With Rare Disease Push In 2025 - News & Insights
Wedge Capital Management L L P NC Trims Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
Brokerages Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Price Target at $77.71 - MarketBeat
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Generics Player ANI Pharmaceuticals Strengthens Rare Disease Segment With $380M Alimera Sciences Deal - MSN
Short Interest in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Declines By 8.5% - MarketBeat
Assenagon Asset Management S.A. Raises Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
ANI Pharmaceuticals (NASDAQ:ANIP) delivers shareholders respectable 12% CAGR over 3 years, surging 6.2% in the last week alone - Simply Wall St
Why Taiwan Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - Benzinga
Is ANI Pharmaceuticals (ANIP) a Great Value Stock Right Now? - Yahoo Finance
Ani Pharmaceuticals senior VP sells $21,568 in stock By Investing.com - Investing.com Australia
Insider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells 400 Shares of Stock - MarketBeat
Ani Pharmaceuticals senior VP sells $21,568 in stock - Investing.com
ANI Pharmaceuticals (NASDAQ:ANIP) Reaches New 52-Week LowHere's What Happened - MarketBeat
Alcami Announces CEO Transition - Quantisnow
ANI Pharmaceuticals Projects Strong Growth for 2025 - TipRanks
ANI Pharmaceuticals, Inc. Affirms Earnings Guidance for the Year 2024 and Provides Earnings Guidance for the Full Year 2025 - Marketscreener.com
ANI Pharmaceuticals Projects Strong 25% Growth for 2025, Exceeds 2024 Guidance Targets - StockTitan
ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook - GlobeNewswire
ANI Continues To Spearhead FDA’s CGT Path With Prucalopride Launch - Citeline
JPMorgan Chase & Co. Raises Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
JPMorgan Chase & Co. Has $33.10 Million Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day Cgt Exclusivity - Marketscreener.com
ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity - The Manila Times
ANI Pharmaceuticals Launches First Generic Motegrity with Exclusive 180-Day Market Access - StockTitan
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Short Interest in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Rises By 27.7% - Defense World
ANI Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
ANI Pharmaceuticals CEO to Present Strategic Vision at J.P. Morgan Healthcare Conference 2025 - StockTitan
Geode Capital Management LLC Grows Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $77.71 Consensus Target Price from Analysts - MarketBeat
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Position Reduced by Wellington Management Group LLP - MarketBeat
State Street Corp Increases Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat
Ani Pharmaceuticals CFO sells $418,425 in stock By Investing.com - Investing.com Nigeria
Insider Sell: Stephen Carey Sells 7,500 Shares of ANI Pharmaceuticals Inc (ANIP) - GuruFocus.com
Stephen P. Carey Sells 7,500 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock - MarketBeat
Ani Pharmaceuticals CFO sells $418,425 in stock - Investing.com
Ani Pharmaceuticals Inc (ANIP) 財務データ
収益
当期純利益
現金流量
EPS
1.19%
0.06%
大文字化:
|
ボリューム (24 時間):